Pegozafermin (BIO89-100): The glycoPEGylated FGF21 Analog Betting on Fibrosis Reversal in MASH (July 10, 2026)
Table of Contents
A liver hormone turned into a drug
Fibroblast growth factor 21 (FGF21) is one of the body's own metabolic regulators. Released mainly by the liver under conditions of fasting and metabolic stress, it signals to the liver, fat tissue, and brain to burn fat, improve insulin sensitivity, lower blood triglycerides, and dial down liver inflammation and scarring. On paper it is almost a perfect target for metabolic dysfunction-associated steatohepatitis (MASH, the condition formerly called NASH) - the aggressive, fibrosing form of fatty liver disease that can progress to cirrhosis and liver failure. The problem is that natural FGF21 is cleared from the blood within hours, far too fast to be a practical medicine. Pegozafermin, originally coded BIO89-100, is 89bio's answer: an engineered FGF21 analog rebuilt to last long enough to work as a once-weekly or once-every-two-weeks injection.
How glycoPEGylation extends the molecule
Pegozafermin uses a technique called site-specific glycoPEGylation. A polyethylene-glycol (PEG) chain is attached to the FGF21 backbone at a precise location through a sugar (glycan) linker, rather than randomly. That targeted attachment shields the protein from the enzymes and clearance pathways that normally chew through native FGF21, stretching its half-life to roughly 55 to 100 hours while leaving the parts of the molecule that engage its receptors free to do their job. Pegozafermin signals through FGF receptor complexes - principally FGFR1c - together with the co-receptor beta-Klotho, which is concentrated in metabolic tissues and gives FGF21 drugs their tissue selectivity. The practical payoff of the long half-life is convenience: weekly or biweekly dosing instead of the daily injection an unmodified hormone would demand.
The ENLIVEN data: hitting fibrosis, not just fat
The reason pegozafermin matters is the Phase 2b ENLIVEN trial in patients with biopsy-confirmed F2-F3 (moderate-to-advanced, non-cirrhotic) MASH. Regulators have made clear that the endpoints that count in MASH are histologic: measurable improvement in fibrosis and resolution of steatohepatitis on a liver biopsy, not just a drop in liver fat on a scan. ENLIVEN delivered on both. At the 44 mg every-two-weeks dose, about 27% of patients achieved at least a one-stage improvement in fibrosis without worsening of MASH, versus roughly 7% on placebo, and about 26% achieved MASH resolution without worsening of fibrosis, versus about 2% on placebo. Both results were statistically significant and were sustained through week 48, alongside reductions in liver fat, liver enzymes, and triglycerides. Those numbers put pegozafermin among the most convincing mid-stage MASH datasets in the FGF21 class.
Roche's $3.5 billion bet and the ENLIGHTEN program
In September 2025, Roche announced a definitive agreement to acquire 89bio for approximately $2.4 billion in cash upfront, plus a contingent value right of up to about $6.00 per share tied to future milestones - a potential total of around $3.5 billion. For Roche, pegozafermin is a late-stage entry point into MASH and cardiometabolic disease, a field it has been building through deals like the Carmot acquisition (which brought the incretin CT-388). Pegozafermin carries an FDA Breakthrough Therapy designation and EMA PRIME status for MASH, and it has moved into a two-trial Phase 3 program: ENLIGHTEN-Fibrosis, enrolling roughly 1,000 non-cirrhotic F2-F3 MASH patients across 30 mg weekly, 44 mg every-two-weeks, and placebo arms with co-primary histology endpoints at week 52; and ENLIGHTEN-Cirrhosis (NCT06419374), testing 30 mg weekly against placebo in about 760 patients with compensated F4 cirrhosis, where the bar is fibrosis regression out of cirrhosis. A separate Phase 3, ENTRUST, targets severe hypertriglyceridemia.
FGF21 versus the incretins - and why they may combine
Pegozafermin sits in a different lane from the GLP-1-based drugs that dominate obesity coverage. Its closest competitor is efruxifermin, another long-acting FGF21 analog chasing the same MASH endpoints, and the two are effectively defining what FGF21 can do in fibrotic liver disease. Against the incretins, the contrast is mechanistic: drugs like semaglutide, tirzepatide, survodutide, and the triple agonist efocipegtrutide reduce liver fat largely by driving weight loss and appetite suppression, whereas FGF21 analogs act directly on liver and lipid metabolism and lower triglycerides without being weight-loss drugs. That difference is exactly why many researchers see FGF21 agents not only as standalone therapies but as future combination partners for incretins - pairing an appetite-and-weight mechanism with a direct anti-fibrotic, lipid-lowering one. Whether that promise holds depends on the Phase 3 histology readouts still to come.
What to watch and the safety caveats
Pegozafermin is investigational and not approved anywhere; it cannot be prescribed, and anything sold online as 'pegozafermin' or 'FGF21' is not the clinical drug and cannot be assumed authentic, pure, or safe. In trials the most common adverse effects have been gastrointestinal (nausea, diarrhea) and injection-site reactions, generally mild-to-moderate; the FGF21 class as a whole is also being watched for possible effects on appetite, bone-turnover markers, and blood pressure whose long-term significance is not yet settled. The ENLIVEN results are a strong mid-stage signal, but they come from a 24-to-48-week trial using histology and biomarkers as surrogates - the questions that matter for patients (does it prevent progression to cirrhosis and liver-related events, and is it safe over years) are what the ENLIGHTEN Phase 3 program is built to answer. For now, pegozafermin is one of the clearest tests of whether directly engaging the FGF21 pathway can reverse the scarring of MASH.
Ready to track your peptide research?
Open PepTracker ProPepTracker Pro Research Team
The PepTracker Pro Research Team is an editorial group of science writers, pharmacologists, and clinical researchers dedicated to making peptide science accessible. Every article is reviewed for accuracy against peer-reviewed sources and updated as new evidence emerges.
Citations
- [1] Randomized, Controlled Trial of the FGF21 Analogue Pegozafermin in NASH (ENLIVEN) - NEJM Source
- [2] Roche enters into a definitive merger agreement to acquire 89bio and its Phase 3 FGF21 analog for MASH - Roche (Sept 18, 2025) Source
- [3] 89bio Initiates Phase 3 ENLIGHTEN-Fibrosis Trial of Pegozafermin in Non-Cirrhotic MASH - 89bio Source
- [4] A Study to Evaluate Pegozafermin in Compensated Cirrhosis Due to MASH (ClinicalTrials.gov NCT06419374) Source
- [5] 89bio Receives EMA PRIME Status for Pegozafermin in MASH with Fibrosis and Compensated Cirrhosis - 89bio Source
Related Articles
A comprehensive guide to GLP-1 receptor agonists — how they work, what sets them apart, and where the science is heading.
Efocipegtrutide (HM15211): Hanmi's GLP-1/GIP/Glucagon Triple Agonist Aims at Liver Disease, Not Just Weight (July 9, 2026)
Most triple agonists chase weight loss. Hanmi's efocipegtrutide (HM15211) is built for the liver: a once-weekly GLP-1/GIP/glucagon agonist whose glucagon arm drives energy expenditure and direct anti-fibrotic effects in MASH. Here's how the LAPSCovery Fc-fusion design works, what the liver-fat data show, and why its MASH-first, orphan-designated positioning sets it apart from retatrutide.